Rocket's KRESLADI has endured several FDA delays but will likely see a new BLA filing in the near future. Read why I'm ...

CK Hutchison's subsidiary recently disclosed plans for a secondary listing in the UK, and there are expectations that CKHUY.

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: ...

Good afternoon, and welcome to the Third Quarter Fiscal 2024 Hewlett Packard Enterprise Earnings Conference Call. My name is ...

There are two things in life that'll bring you down to size: dating in New York City and applying for a job in 2024. The ...

Q4 2024 Earnings Call Transcript September 10, 2024 Operator: Good morning. Welcome to today’s Bioceres Crop Solutions, ...

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured ...

Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer ...

Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately 7.1% of Dye & Durham Limited's (TSX: DND) ("Dye & Durham" or the "Company") outstanding shares, today ...

Welcome to Zenvia’s Q2 2024 Earnings Conference Call. Today’s speakers are Mr. Cassio Bobsin, Zenvia’s Founder and CEO; and ...

Still, safety concerns could temper Dyne’s hopes, as revealed in a company presentation from the biotech’s phase 1/2 DELIVER trial. On a slide covering DYNE-251’s safety profile, the biotech ...